AKAlexander A. Kolobov

Alexander A. Kolobov

*This is an algorithmically generated author record based on publicly available information.

Alexander A. Kolobov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Study of Recombinant Interleukin-1 Receptor Antagonist Compositions Biological Activity After Injection and Inhalation in Mouse Model of Pulmonary Inflammation

    by Alexander M. Ischenko, Kseniya A. Nekrasova, Denis S. Laptev, Dmitry V. Bobkov, Alexander A. Kolobov, Andrey S. Simbirtsev, Симбирцев Андрей Семенович

    BACKGROUND: The severity of respiratory distress syndrome is associated with the development of systemic multifactorial inflammatory processes leading to hyperinflammation. Proinflammatory cytokines, primarily interleukin-1 (IL-1), and reactive oxygen species substantially contribute to these pathological processes. The use of an interleukin-1 receptor antagonist (IL-1Ra) as an IL-1 blocker is a key first-line therapy for patients experiencing cytokine storm syndrome. The novelty of the approach under investigation lies in studying the effectiveness of inhaled administration of IL-1Ra, including its combined use with a reactive oxygen species inhibitor — superoxide dismutase (SOD). AIM: To assess the efficacy of IL-1Ra administered parenterally and by inhalation, both as a standalone agent and in combination with SOD, in a bleomycin-induced acute respiratory distress syndrome model. MATERIALS AND METHODS: Male BALB/c mice were used in the study. Respiratory distress syndrome was modeled by intraperitoneal administration of bleomycin at a dose of 2 mg/mouse on days 1, 8, and 15 of the experiment. The investigational drugs—a 10.0-mg/mL IL-1Ra solution and a 10.0-mg/mL IL-1Ra solution containing 0.4 mg/mL SOD—were administered to the experimental groups either subcutaneously or by inhalation at a dose of 2 mg/mouse daily for 15 days starting from day 1 of the experiment. Body weight, spirometry, histological studies, and animal survival were assessed. RESULTS: Subcutaneous and inhalation administration of IL-1Ra + SOD, as well as subcutaneous administration of IL-1Ra, positively affected animal survival. Subcutaneous administration of IL-1Ra and IL-1Ra + SOD led to statistically significant improvements in indicators of external respiration in mice with bleomycin-induced intoxication. A reduction in destructive lung changes caused by intraperitoneal administration of bleomycin was observed in the experimental groups receiving inhaledIL-1Ra orIL-1Ra + SOD and in the group receiving subcutaneous IL-1Ra. CONCLUSION: Both investigational products — IL-1Ra and IL-1Ra + SOD — administered by injection or inhalation demonstrated a positive effect in the treatment of respiratory distress syndrome induced by bleomycin in the mouse model.